New alliance for emerging biotechs

The New York Biotechnology Association and the New York Academy of Sciences have announced an alliance designed to give emerging biotechnology companies reduced price access to NYAS corporate membership.

The new "Growth Partners" program will let emerging biotechnology companies who are NYBA members take advantage of the many programming and networking opportunities that corporate membership provides. Current members include larger companies such as Pfizer, Bristol-Myers Squibb and IBM. However, including earlier-stage companies through "Growth Partners" will bring an increased level of entrepreneurship and access to even more cutting-edge science in the NYAS network and its scientific programming. To capitalize on this, there are plans to inaugurate an annual event at the Academy to focus on earlier-stage industry innovation and highlight NYBA members who become Growth Partners.

With more than 25,000 members in 140 countries, the NYAS says it offers businesses a competitive edge by providing unparalleled access to thought leaders at the cutting edge of innovation. Through initiatives such as the Frontiers of Science program, NYAS corporate members enjoy access to unique networking opportunities in some of the hottest fields in science. Additionally, the Academy's Science Alliance provides access to a network of young scientists including over 6,000 of the brightest from over 30 of the top universities in the USA and around the world, says the Association.